Xianquan Zhan

Shandong First Medical University

Prof. Xianquan Zhan received his M.D. and Ph.D. training in preventive medicine at West China University of Medical Sciences during 1989-1999. He received his post-doctoral training in oncology and cancer proteomics at Central South University and University of Tennessee Health Science Center (UTHSC). He worked at UTHSC and Cleveland Clinic in USA during 2001-2012, and achieved the rank of Associate Professor at UTHSC. In 2012, he moved to Central South University and Shandong First Medical University as a Professor, and Advisor of MS/PhD graduate students and postdoctoral fellows. He is also the Fellow of Royal Society of Medicine, Fellow of EPMA, European EPMA National Representative, Full member of ASCO, AAAS member, Editor-In-Chief of IJCDT, Associate Editors of EPMA Journal and BMC Genomics, and Guest Editors of Frontiers in Endocrinology and Mass Spectrometry Reviews. He has published 138 articles, 25 book chapters, and is a holder of 2 US patents in the field of clinical proteomics and biomarkers. He edited 4 academic books: Proteoforms – Concept and Applications in Medical Sciences, Molecular Network Study of Pituitary Adenomas, and Ubiquitin-Proteasome Pathway. As the Guest editor, he edited 11 special issues in SCI journals such as Mass Spectrometry Reviews, Frontiers in Endocrinology, EPMA Journal, and Med One. His main research interest focuses on the studies of cancer proteomics and proteoforms, multiomics and biomarkers, and the use of modern omics techniques and systems biology for predictive, preventive and personalized medicine (PPPM) and precision medicine (PM) in cancer.

2books edited

8chapters authored

Latest work with IntechOpen by Xianquan Zhan

The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 enzymes, E2 enzymes, E3 enzymes, and proteasome, which acts in a series of enzymatic reaction chains to ubiquitinate substrate proteins such as surplus and misfolded proteins for degradation by the proteasome to maintain the balance between protein synthesis and degradation in a cell and tissue. Moreover, deubiquitinating enzymes can remove the attached ubiquitin chain, which results in a reverse ubiquitination-deubiquitination process involved in multiple biological processes in a cell and tissue. The changes of components in the ubiquitin-proteasome pathway are associated with multiple pathophysiological processes, such as cancers and neurodegenerative diseases. This book presents the new advances in concepts, analytical methodology, and application of ubiquitin-proteasome pathway for clarification of molecular mechanisms and discovery of new therapeutic targets and drugs in different diseases.

Go to the book